


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13 (cancelled)

Claim 14 (currently amended): A compound which is 1-[2-(2-ethyl-2H-tetrazol-5-yl)-ethyl]-3-[5-(3-fluoro-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-urea of formula I



in free or salt form, wherein _____

~~R^a is hydrogen or C₁-C₄-alkyl, R^b is C₁-C₈-alkyl substituted by pyridyl, R³ is R⁶, and R⁴ is fluoro or C₁-C₈-haloalkyl,~~

~~or R^a is hydrogen or C₁-C₄-alkyl, R^b is C₁-C₈-alkyl substituted by hydroxy or nitrile, R³ is R⁶, and R⁴ is hydrogen or C₁-C₈-haloalkyl,~~

~~or R^a is hydrogen or C₁-C₄-alkyl, R^b is C₁-C₈-alkyl substituted by nitrile, R³ is fluoro, and R⁴ is R⁷,~~

~~or R^a is hydrogen or C₁-C₄-alkyl, R^b is C₁-C₈-alkyl substituted by hydroxy, R³ is fluoro, and R⁴ is R⁷,~~

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by di(C_1-C_8 -alkyl)amino, R^3 is R^6 ,
and R^4 is C_1-C_8 -haloalkyl;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by $O-C_1-C_8$ -alkyl-OH, R^3 is R^6 ,
and R^4 is fluoro or C_1-C_8 -haloalkyl;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is $CH(CH_3)-CH_2-OH$, R^3 is R^6 , and R^4 is fluoro;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by pyrrolidinyl substituted by
 C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is C_1-C_8 -haloalkyl;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by oxazolyl substituted by
 C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is nitrile or imidazolyl;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by imidazolyl, R^3 is R^6 , and R^4 is
fluoro;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by benzoimidazolyl, R^3 is R^6 , and
 R^4 is fluoro;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by isoxazolyl substituted by
 C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by pyrrolyl substituted by
 C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by pyrazolyl substituted by
 C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by ~~CO-O-CH₃, CO-O-butyl,~~
~~CO-di(C_1-C_8 -alkyl)amino, CO-NH₂, NH-CO- C_1-C_8 -alkyl, SO₂- C_1-C_8 -alkyl, CO-NH- R^6~~
where R^6 is naphthyl, or by ~~CO-NH- C_1-C_8 -alkyl~~ optionally substituted by di(C_1-C_8 -alkyl)-amino,
 R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is ~~CH(CH₃)-CO-NH- C_1-C_8 -alkyl or~~
~~CH(CH₃)-CO-O- C_1-C_8 -alkyl,~~ R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by ~~CH(OH)-CH₂-OH,~~ R^3 is R^6 ;
and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by C_1-C_8 -alkoxy, or by ~~S- C_1-C_8 -~~
alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by a 5- or 6-membered
heterocyclic ring having one or more ring hetero atoms selected from the group consisting of
oxygen, nitrogen and sulphur, that ring being substituted by oxo, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by a 5- or 6-membered
heterocyclic ring having three or more ring hetero atoms selected from the group consisting of
oxygen, nitrogen and sulphur, that ring being optionally substituted by C_1-C_8 -alkyl,
 ~~C_1-C_8 -alkyl-di(C_1-C_8 -alkyl)amino, or by C_3-C_8 -cycloalkyl,~~ R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by oxazolyl substituted by
 C_3-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by imidazolyl substituted by C_1-C_8 -alkyl optionally substituted by hydroxy or C_1-C_8 -alkoxy, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is C_1-C_8 -alkyl substituted by $CO-Het$ where Het is a 5- or 6-membered heterocyclic ring having two or more ring hetero-atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is a 5- or 6-membered heterocyclic ring having one or more ring hetero-atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being substituted by oxo, R^3 is R^6 , and R^4 is R^7 ;

or R^a is hydrogen or C_1-C_4 -alkyl, R^b is an aza-bicyclo[3.2.1]oct-3-yl ring optionally substituted by C_1-C_8 -alkyl, R^3 is R^6 , and R^4 is R^7 ;

or R^a and R^b together form an azetidine ring substituted by C_1-C_8 -alkoxycarbonyl or nitrile, R^3 is R^6 , and R^4 is R^7 ;

or R^a and R^b together form a pyrrolidine ring substituted by $CO-NH_2$ or nitrile, R^3 is R^6 , and R^4 is R^7 ;

or R^a and R^b together form an imidazo-pyridine ring, R^3 is R^6 , and R^4 is R^7 ;

R^2 is C_1-C_4 -alkyl or halogen;

R^5 is hydrogen, halogen or C_1-C_8 -alkyl;

~~R⁶ is halo, SO₂-CH₃, SO₂-CF₃, carboxy, CO-NH₂, CO-di(C₁-C₈-alkyl)amino, or a 5- or 6-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C₃-C₈-cycloalkyl, C₁-C₈-alkylcarbonyl, C₁-C₈-alkoxy optionally substituted by aminocarbonyl, or C₁-C₈-alkyl optionally substituted by hydroxy, C₁-C₈-alkoxy, C₁-C₈-alkylamino or di(C₁-C₈-alkyl)amino;~~

~~R⁷ is hydrogen, halo, SO₂-CH₃, nitrile, C₁-C₈-haloalkyl, imidazolyl, C₁-C₈-alkyl, NR⁸R⁹, or -SO₂-NR⁸R⁹; and~~

~~R⁸ and R⁹ are independently hydrogen, amino, C₁-C₈-alkylamino, di(C₁-C₈-alkyl)amino, or C₁-C₈-alkyl optionally substituted by hydroxy, or R⁸ and R⁹ together form a 5- to 10-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C₃-C₈-cycloalkyl, C₁-C₈-alkylcarbonyl, C₁-C₈-alkoxy optionally substituted by aminocarbonyl, or C₁-C₈-alkyl optionally substituted by hydroxy, C₁-C₈-alkoxy, C₁-C₈-alkylamino or di(C₁-C₈-alkyl)amino.~~

Claims 15-19 (cancelled)


Claim 20 (currently amended): A pharmaceutical composition comprising a compound according to claim 14, in free or salt form.

Claim 21 (withdrawn-currently amended): A method of treating a disease mediated by phosphatidylinositol 3-kinase in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 14 in free form or in the form of a pharmaceutically acceptable salt.


Claim 22 (withdrawn-currently amended): A method of treating respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity or restenosis in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 14 in free form or in the form of a pharmaceutically acceptable salt.


Claim 23 (withdrawn-currently amended): A process for ~~the preparation of~~ preparing a compound ~~of formula I~~ as defined in claim 14, in free or salt form which comprises the steps of:

(i) (A) reacting a compound of formula II




wherein R^2 , R^3 , R^4 and R^5 are as claimed in claim 14 and T is a 5- or 6-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, with a compound of formula III





wherein R^a and R^b are as claimed in claim 14; or


(B) reacting compounds a compound of formula IV




wherein R^2 , R^3 , R^4 and R^5 are as claimed in claim 14 with a compound of formula III



wherein R^a and R^b are as claimed in claim 14; or

(C) for the preparation of compounds of formula I where R^a is hydrogen and R^2 , R^3 , R^4 , R^5 and R^b are as claimed in claim 14, reacting a compound of formula V






wherein R^2 , R^3 , R^4 and R^5 are as claimed in claim 14, with a compound of formula VI



wherein R^b is as claimed in claim 14; or

(D) for the preparation of compounds of formula I where R^a is hydrogen, R^b is C_1 - C_8 -alkyl substituted by imidazolyl substituted by C_1 - C_8 -alkyl optionally substituted by hydroxy or C_1 - C_8 -alkoxy and R^2 , R^3 , R^4 and R^5 are as claimed in claim 14, reacting a compound of formula V where R^2 , R^3 , R^4 and R^5 are as claimed in claim 14, with a compound of formula VII



where Q is C_1 - C_8 -alkyl optionally substituted by hydroxy or C_1 - C_8 -alkoxy; and

- (ii) recovering the resultant compound of formula I in free or salt form.